Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

0 patients from sites throughout Europe, South America, Asia Pacific and the Middle East.

About Non-Small Cell Lung Cancer (NSCLC)(1)

Non-small cell lung cancer accounts for 85-90% of diagnosed lung cancers and is a disease in which malignant (cancer) cells form in the tissues of the lung. It is characterized by several types of lung cancers, each of which grow and spread in different ways, including: squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.

Every year 1.4 million people worldwide will be diagnosed with lung cancer.  There are nearly 205,000 new cases in the United States and approximately 375,000 new cases in Europe each year.  Annual deaths as a result of non small cell lung cancer are estimated at 160,000 in the United States and 342,000 in Europe.

Nexavar's Differentiated Mechanism
Nexavar, an oral anti-cancer therapy, is currently approved in more than 90 countries for liver cancer and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigat
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... SAN FRANCISCO, Calif. , July 6, 2015 /PRNewswire/ ... global pharmaceutical company, and Oculeve, a development-stage medical device ... disease, today announced that they have entered into an ... all-cash transaction.  Under the terms of the agreement, Allergan ... and commercialization milestone payments related to Oculeve,s lead development ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or "CNIT") (Nasdaq ... exchange, and big data solutions in China ... mobile app for Healthcare One Pass, ushering in a ... The Company jointly hosted the launch ceremony with the ... News Net.   The mobile app for Healthcare ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... hospitals scramble to adopt the patient-centered focus that is ... at improving healthcare in the U.S., LodgeNet Healthcare ... engagement solution that encourages patients to become educated, active ... to interact with patients throughout the entire continuum of ...
... EAST BRUNSWICK, N.J. and EDISON, N.J., June 8, ... today announced they had entered into a broad-based ... controlled release products. Under the terms of the ... develop and manufacture products for Amerigen to commercialize ...
Cached Medicine Technology:LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 2LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 3LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 4Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products 2
(Date:7/6/2015)... ... July 06, 2015 , ... Respected southern California personal ... in 2015, marking him as an attorney who has sharp legal skills as well ... Client Distinction Award for 2015 from Martindale-Hubbell and a Top 10 Award from The ...
(Date:7/6/2015)... ... , ... University of Pittsburgh Cancer Institute (UPCI) scientists recently led ... newly available tests that better incorporate personalized medicine into diagnosing the condition. , ... is published in the July issue of the scientific journal Thyroid . ...
(Date:7/6/2015)... ... July 06, 2015 , ... Shortly after opening her ... the leading network of doctors working on a lien basis. Dr. Lim had ... , The daughter of two Cambodian refugees, Dr. Lim suffered with back pain herself ...
(Date:7/6/2015)... ... July 06, 2015 , ... Hundreds of thousands of ... which is why liposuction regularly ranks among the top five most popular cosmetic ... become more than a way to slim down a silhouette for swimsuit season. ...
(Date:7/6/2015)... ... July 06, 2015 , ... Understanding ... services and ADVOCATE is leading the transition. ADVOCATE, the only 100% radiology, revenue ... Top 10 Tips for ICD-10. The ten tips are timely and relevant guidelines ...
Breaking Medicine News(10 mins):Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 2Health News:Fernando D. Vargas Awarded Top Honors in Personal Injury Law for 2015 from Two Respected Independent Organizations 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2
... Products, Ltd. is,launching its latest new pill case designs ... was invented in-house to address,ease-of-use concerns. The new look ... 2008 Best of Rochester Award in the Industrial Designers,category ... The VitaCarry(R) and VitaBuddy(R) brands ...
... announced today that Dr. Jonathan White will join the Company ... effective December 8, 2008. In this role, Dr. White ... generation of products to complement Haemonetics, blood management solutions portfolio. ... Chairman and CEO, said, "As the global leader in blood ...
... Dec. 8 It,s no secret: Ties are,typically major ... risk,to health and life itself. But now, there,s a ... new additions to SafetyTies collection of antimicrobial,neckties: the HAI ... Featuring colorful, artistic renditions of microorganisms, the ...
... Triple-S,Management Corporation (NYSE: GTS ), the largest ... has converted seven million issued and,outstanding Class A shares ... expiration of the lockup agreements signed by holders of,Class ... public offering. It is,expected that the newly converted Class ...
... manufacturer and marketer of nutritional supplements, today announced preliminary unaudited net sales results for the month of November 2008. , ... as follows: , , , , ... NET SALES, ... ...
... SAN DIEGO, Dec. 8 This January 7-11 in ... present its most exclusive,life-transforming workshop, "SynchroDestiny," led by best-selling ... and David,Simon. , ... For more than a decade, "SynchroDestiny" ...
Cached Medicine News:Health News:NEW Line of Pushbutton Pill Cases Launched by Variant Products 2Health News:Dr. Jonathan White Joins Haemonetics as Head of Research and Development 2Health News:SafetyTies Keep Getting Safer: Newest Neckties Reduce the Spread of Germs and Stylishly Feature the Microbes They Fight 2Health News:Triple-S Management Corporation Announces Conversion of Class A Shares and Commencement of Class B Stock Repurchase Program 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for November 2008 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for November 2008 3Health News:NBTY Announces Preliminary Unaudited Net Sales Results for November 2008 4Health News:Start 2009 with The Chopra Center's Signature Self-Empowerment Workshop 2
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications....
... is a fixed wavelength fluorometer for ... emission. The spectral characteristics are specifically ... DNA using the standard Hoechst 33258 ... from the presence of protein, RNA, ...
The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....
Medicine Products: